Clinical Trial

Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine if neoadjuvant (treatment before surgery) immunotherapy treatment based on tumor biomarkers results in better participant outcomes. Immunotherapy is the treatment of disease by using a person's own immune system. This study is divided into 2 sub-studies/parts designated Part 1 and Part 2 that will enroll in sequence starting with Part 1 followed by Part 2.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2024-03-05; most recent amendment 2026-03-31.
Status change: Not Yet Recruiting → Recruiting 2024-03-06
Trial Details
NCT Number NCT06295159
Lead Sponsor H. Lee Moffitt Cancer Center and Research Institute
Collaborators: Bristol-Myers Squibb
Conditions Melanoma Stage III, Melanoma Stage IV, Advanced Melanoma, Melanoma
Enrollment 90 participants
Start Date 2024-05-17
Primary Completion 2028-11 (estimated)
Study Completion 2028-11 (estimated)
Updated on ClinicalTrials.gov 2026-04-01